

July 28, 2023

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Outcome of Board Meeting of the Company held on July 28,2023

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has at its meeting held on Friday, July 28, 2023, inter-alia, considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2023.

The said Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 03:00 p.m. and concluded at 05:30 p.m.

Kindly take the same on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

RAJESH RAMESH SHIRAMBEKAR
Digitally signed by RAJESH RAMESH SHIRAMBEKAR
Date: 2023.07.28 17:46:23 +05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary



Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & C O L L P
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

Aruna

per Aruna Kumaraswamy
Partner
Membership No.: 219350
UDIN: 23219350BGXWIJ3264



Place: Mumbai
Date: July 28, 2023

(Rs. in Lakhs)

Statement of Financial Results for the quarter ended 30th June 2023

Particulars	Quarter ended			Year ended
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
	(Unaudited)	(Audited) (Refer Note 3)	(Unaudited)	(Audited)
1 Revenue from Operations	14,778	11,849	12,893	51,281
2 Other Income	181	184	122	480
3 Total Income	14,959	12,033	13,015	51,761
4 Expenses				
(a) Cost of Materials Consumed	3,047	2,242	2,126	8,612
(b) Purchases of Stock-in-Trade	1,666	2,026	2,012	9,205
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	305	(319)	216	(730)
(d) Employee Benefits Expense	3,279	3,377	2,708	11,706
(e) Finance Costs	7	5	11	31
(f) Depreciation and Amortisation Expense	421	389	383	1,550
(g) Other Expenses	3,257	2,932	3,047	12,219
Total Expenses	11,982	10,652	10,503	42,593
5 Profit before tax (3-4)	2,977	1,381	2,512	9,168
6 Income tax expenses				
a. Current Tax	792	369	658	2,435
b. Deferred Tax	(25)	(23)	33	(31)
7 Profit for the period (5-6)	2,210	1,035	1,821	6,764
8 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	2	36	(9)	9
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(1)	(9)	2	(2)
Other Comprehensive Income Net of Tax	1	27	(7)	7
9 Total Comprehensive Income for the period (7+8)	2,211	1,062	1,814	6,771
10 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323
11 Other Equity				29,437
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				
(a) Basic	13.36	6.26	11.01	40.90
(b) Diluted	13.36	6.26	11.01	40.90


Notes:

- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meetings held on July 28, 2023.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- The figure of above quarter ended 31 March, 2023 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures upto 31 December, 2022, which were subject to limited review.
- During the quarter ended 30th June 2022, the Company exercised the option of lower tax rate under Section 115 BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 effective April 01, 2022. Accordingly, the Company had adopted the new tax rate of 25.17% which had resulted in a reversal of deferred tax balance of Rs 46 lakhs in quarter ended June 30, 2022 on account of remeasurement of deferred tax balance as at 31st March, 2022.
- Previous period's figures have been regrouped/reclassified wherever necessary.

SIGNED FOR IDENTIFICATION
 BY

SRBC & CO LLP
 MUMBAI

For RPG Life Sciences Limited


 Yugal Sikri
 Managing Director
 Mumbai, July 28, 2023
 B.M. DP JK